Direkt zum Inhalt
Merck

Calcineurin inhibitors: 40 years later, can't live without ...

Journal of immunology (Baltimore, Md. : 1950) (2013-12-10)
Jamil R Azzi, Mohamed H Sayegh, Samir G Mallat
ZUSAMMENFASSUNG

Calcineurin inhibitors (CNIs) revolutionized the field of organ transplantation and remain the standard of care 40 years after the discovery of cyclosporine. The early impressive results of cyclosporine in kidney transplant recipients led to its subsequent use in other organ transplant recipients and for treatment of a variety of autoimmune diseases as well. In this review, we examine the discovery of CNIs, their mechanism of action, preclinical and clinical studies with CNIs, and the usage of CNIs in nontransplant recipients. We review the mechanisms of renal toxicity associated with CNIs and the recent efforts to avoid or reduce usage of these drugs. Although minimization strategies are possible, safe, and of potential long-term benefit, complete avoidance of CNIs has proven to be more challenging than initially thought.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Cyclosporin A, 97.0-101.5% (on dried basis)
Sigma-Aldrich
Cyclosporin A, from Tolypocladium inflatum, ≥95% (HPLC), solid
Supelco
Cyclosporin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
FK-506 Monohydrat, ≥98% (HPLC)
Sigma-Aldrich
Cyclosporin A, from Tolypocladium inflatum, BioReagent, Molecular Biology, ≥95%
Supelco
Cyclosporin A -Lösung, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Cyclosporin A, VETRANAL®, analytical standard